EUVIMEDEUVIMED entdecken
Open Access

Development of an Extended-release Formulation of Radioprotectin-1 for Mitigation of Gastrointestinal Acute Radiation Syndrome

Derek D Norman, Sue Chin Lee, Yoojin Shin, Mohamed M Ibrahim, Monica M Jablonski, Yingzhe Wang, Louisa Balázs, Erika W Davies, Zoltán Benyó, Gábor J Tigyi

Radiation Research · 27.01.2026 · 205 (4) · 414-428

DOI: 10.1667/rade-25-00188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Research, erschienen am 27.01.2026. Verfasst von Derek D Norman und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Acute Radiation Syndrome, Radiation-Protective Agents, Gastrointestinal Tract. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Left unmitigated, high-dose ionizing radiation causes DNA damage resulting in cell death and manifestation of the acute radiation syndrome (ARS). Activation of the lysophosphatidic acid receptor subtype 2 (LPAR2) is one mechanism by which radiation damage can be mitigated. Our laboratory has previously developed 5-chloro-2-(N-(4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)sulfamoyl)benzoic acid, designated as Radioprotectin-1 (RP-1), which is a potent LPAR2-specific agonist and radiation mitigator. We previously reported that an aqueous (AQ) formulation of RP-1 provides significant survival advantage in a murine gastrointestinal ARS (GI-ARS) model when given in a three-day regimen of twice-daily subcutaneous injections administered starting 24 h after irradiation. To improve the dosing formulation suitable for the field treatment of mass casualties, an extended-release dosing regimen was developed utilizing a water-in-oil-in-water (W/O/W) multilayered microemulsion (ME) formulation. The ME significantly extended plasma half-life, mean residence time, and exposure time while slowing plasma clearance compared to the AQ formulation in C57BL/6J mice as well as in non-human primates (NHP). This formulation provides a significant survival advantage in a GI-ARS model with only two subcutaneous injections at 24 and 72 h postirradiation. Additionally, RP-1 ME treatment protects intestinal crypts in irradiated mice, resulting in an increase in both total and actively regenerating crypts at day 5 postirradiation. Finally, LPAR2 activation by RP-1 leads to prolonged and sustained activation of the pro-survival kinases ERK1/2 and Akt up to 16 h postirradiation and reduces caspase-mediated apoptosis in irradiated mouse embryonic fibroblasts, providing a mechanism for RP-1 radiation mitigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Radiation SyndromeRadiation-Protective AgentsGastrointestinal TractAnimalsMiceDelayed-Action Preparations

Substanzen

Radiation-Protective AgentsDelayed-Action Preparations

Förderung

  • NIAID NIH HHS

Zitieren

APA

Norman, D. D., Lee, S. C., Shin, Y., Ibrahim, M. M., Jablonski, M. M., Wang, Y., Balázs, L., Davies, E. W., Benyó, Z., & Tigyi, G. J. (2026). Development of an Extended-release Formulation of Radioprotectin-1 for Mitigation of Gastrointestinal Acute Radiation Syndrome. Radiation Research, 205(4), 414-428. https://doi.org/10.1667/rade-25-00188

Vancouver

Norman DD, Lee SC, Shin Y, Ibrahim MM, Jablonski MM, Wang Y, et al. Development of an Extended-release Formulation of Radioprotectin-1 for Mitigation of Gastrointestinal Acute Radiation Syndrome. Radiation Research. 2026;205(4):414-428. doi:10.1667/rade-25-00188

BibTeX
@article{Norman2026,
  author = {Norman, Derek D and Lee, Sue Chin and Shin, Yoojin and Ibrahim, Mohamed M and Jablonski, Monica M and Wang, Yingzhe and Balázs, Louisa and Davies, Erika W and Benyó, Zoltán and Tigyi, Gábor J},
  title = {Development of an Extended-release Formulation of Radioprotectin-1 for Mitigation of Gastrointestinal Acute Radiation Syndrome},
  journal = {Radiation Research},
  year = {2026},
  volume = {205},
  number = {4},
  pages = {414--428},
  doi = {10.1667/rade-25-00188}
}
Kostenlos starten →